April 15, 2015—The Department of Health and Human Services Office of Inspector General has told two members of Congress that it plans to determine the amount of additional rebates Medicaid would have received if generic drugs were subject to the same penalty as brand-name drugs when their prices rise faster than the rate of inflation.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)